<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901104</url>
  </required_header>
  <id_info>
    <org_study_id>Long-term prognosis in sepsis</org_study_id>
    <nct_id>NCT04901104</nct_id>
  </id_info>
  <brief_title>Long-term Prognosis of Patients With Sepsis After Immunotherapy</brief_title>
  <official_title>Long-term Prognosis After Thymosin Alpha 1 Treatment in Patients With Sepsis: A Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes&#xD;
      (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year&#xD;
      mortality) of patients with sepsis after immunotherapy.&#xD;
&#xD;
      Based on the preliminary clinical study (NCT02867267), this study will conduct long-term&#xD;
      follow-up for sepsis patients to provide data support for the long-term prognosis of&#xD;
      immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>three years mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Mortality rate of patients treated with thymosin α1 or placebo within 3 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of sepsis</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of recurrent sepsis within 5 years of discharge sepsis patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>one year mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Mortality rate of patients treated with thymosin α1 or placebo within 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Five years mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Mortality rate of patients treated with thymosin α1 or placebo within 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>short form 36 questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life of sepsis patients after 1 year of thymosin α1 or placebo treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Long-term Effects of Thymosin Alpha 1 Treatment</condition>
  <arm_group>
    <arm_group_label>thymosin α1 group</arm_group_label>
    <description>The patient was treated with thymosin α1 in sepsis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <description>The patient was treated without thymosin α1 in sepsis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymosin Alpha1</intervention_name>
    <description>Drug interventions have been done in previous clinical studies</description>
    <arm_group_label>thymosin α1 group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Sepsis patients who discharged from hospital after recovery in the TESTS study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sepsis patients in the TESTS study Patients who discharged from hospital after&#xD;
             recovery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianfeng Wu</last_name>
    <phone>020-87755766-8453</phone>
    <email>wujianf@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fei Pei</last_name>
    <phone>020-87755766-8453</phone>
    <email>peif3@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/study/NCT02867267</url>
    <description>This study is a follow-up study of TESTS study</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Wu Jianfeng</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>long-term</keyword>
  <keyword>thymosin alpha 1</keyword>
  <keyword>sepsis</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

